Islet transplantation and encapsulation: An update on recent developments

Review of Diabetic Studies

Volumn 8, Issue 1, 2011, Pages 51-67

  Vaithilingam, Vijayaganapathy ^a,b   Tuch, Bernard E ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Australian Foundation for Diabetes Research   (Australia)

Author keywords

Alginate poly l lysine; Encapsulation; Islet transplantation; Microcapsules; Pericapsular fibrotic overgrowth; Sulphated glucomannanbarium alginate

Indexed keywords

ALEMTUZUMAB; ALGINATE POLYLYSINE ALGINATE; ALGINIC ACID; AZATHIOPRINE; BARIUM DERIVATIVE; BELATACEPT; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; INSULIN; MANNURONIC ACID; POLYACRYLONITRILE; POLYVINYLCHLORIDE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTOME;

ALLOTRANSPLANTATION; BIOCOMPATIBILITY; BONE MARROW SUPPRESSION; CELL ENCAPSULATION; CELL PROTECTION; CELL SURVIVAL; CELL THERAPY; CONSTIPATION; DIABETOGENESIS; DISEASE MODEL; DISPERSION; DYSLIPIDEMIA; EDEMA; FATIGUE; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT REJECTION; HIRSUTISM; HUMAN; HYDROGEL; HYPERTENSION; HYPOXIA; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; KIDNEY DISEASE; MICROCAPSULE; MICROENCAPSULATION; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PREDICTION; REVIEW; SIDE EFFECT; SURGICAL RISK; ULCER; CYTOLOGY; GRAFT SURVIVAL; IMMUNOLOGY; METABOLISM; METHODOLOGY; PANCREAS ISLET;

DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION;

EID: 80055075197     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2011.8.51     Document Type: Review

References (123)

1. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996. 85(3):291-297.
2. Serup P, Madsen OD, Mandrup-Poulsen T. Islet and stem cell transplantation for treating diabetes. BMJ 2001. 322(7277):29-32.
3. Tapp RJ, Dunstan DW, Phillips P, Tonkin A, Zimmet PZ, Shaw JE. Association between impaired glucose metabolism and quality of life: Results from the Australian diabetes obesity and lifestyle study. Diabetes Res Clin Pract 2006. 74(2):154-161.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993. 329(14):977-986.
5. Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967. 61(6):827-837.
6. Sutherland DE, Moudry KC, Elick BA, Goetz FC, Najarian JS. Pancreas transplant protocols at the University of Minnesota: recipient and donor selection, operative and postoperative management, and outcome. Clin Transpl 1987: 109-126.
7. Cohen DJ, St Martin L, Christensen LL, Bloom RD, Sung RS. Kidney and pancreas transplantation in the United States, 1995-2004. Am J Transplant 2006. 6(5Pt2): 1153-1169.
8. Gruessner RW. Immunosuppression after pancreas transplantation. Transplant Proc 2005. 37:1663-1666.
9. Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery 1972. 72(2):175-186.
10. Scharp DW, Lacy PE, Santiago JV, McCullough CS, Weide LG, Falqui L, Marchetti P, Gingerich RL, Jaffe AS, Cryer PE. Insulin independence after islet transplantation into type I diabetic patient. Diabetes 1990. 39(4):515-518.
11. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000. 343(4):230-238.
12. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006. 355(13):1318-1330.
13. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman MN, Lakey JR, Shapiro AM. Five-year follow-up after clinical islet transplantation. Diabetes 2005. 54(7):2060-2069.
14. Robertson RP, Lanz KJ, Sutherland DE, Kendall DM. Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis. Diabetes 2001. 50(1):47-50.
15. Wiesel M, Carl S. Placebo-controlled study of mycophenolate mofetil used in combination with cyclosporin and corticosteroids for prevention of acute rejection in renal allograft recipients. European Mycophenolate Mofetil Cooperative Study Group. J Urol 1998. 159(1):28-33.
16. Goss JA, Schock AP, Brunicardi FC, Goodpastor SE, Garber AJ, Soltes G, Barth M, Froud T, Alejandro R, Ricordi C. Achievement of insulin independence in three consecutive type 1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation 2002. 74(12):1761-1766.
17. Bell E, Cao X, Moibi JA, Greene SR, Young R, Trucco M, Gao Z, Matschinsky FM, Deng S, Markman JF, Naji A, Wolf BA. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003. 52(11):2731-2739.
18. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007. 7(6):1506-1514.
19. Ichii H, Ricordi C. Current status of islet cell transplantation. J Hepatobiliary Pancreat Surg 2009. 16(2):101-112.
20. Sun AM, Parisius W, Healy GM, Vacek I, Macmorine HG. The use, in diabetic rats and monkeys, of artificial capillary units containing cultured islets of Langerhans (artificial endocrine pancreas). Diabetes 1977. 26(12):1136-1139.
21. Maki T, Lodge JP, Carretta M, Ohzato H, Borland KM, Sullivan SJ, Staruk J, Muller TE, Solomon BA, Chick WL, et al. Treatment of severe diabetes mellitus for more than one year using a vascularized hybrid artificial pancreas. Transplantation 1993. 55(4):713-717.
22. Beck J, Angus R, Madsen B, Britt D, Vernon B, Nguyen KT. Islet encapsulation: strategies to enhance islet cell functions. Tissue Eng 2007. 13(3):589-599.
23. Narang AS, Mahato RI. Biological and biomaterial approaches for improved islet transplantation. Pharmacol Rev 2006. 58(2):194-243.
24. de Vos P, Spasojevic M, Faas M. Treatment of diabetes with encapsulated islets. Adv Exp Med Biol 2010. 670:38-53.
25. Colton CK. Implantable biohybrid artificial organs. Cell Transplant 1995. 4(4):415-436.
26. Scharp DW, Swanson CJ, Olack BJ, Latta PP, Hegre OD, Doherty EJ, Gentile FT, Flavin KS, Ansara MF, Lacy PE. Protection of encapsulated human islets implanted without immunosuppression in patients with type I or type II diabetes and in nondiabetic control subjects. Diabetes 1994. 43(9):1167-1170.
27. Scharp DW, Mason NS, Sparks RE. Islet immunoisolation: the use of hybrid artificial organs to prevent islet tissue rejection. World J Surg 1984. 8(2):221-229.
28. Brauker J, Martinson LA, Young SK, Johnson RC. Local inflammatory response around diffusion chambers containing xenografts. Nonspecific destruction of tissues and decreased local vascularization. Transplantation 1996. 61(12):1671-1677.
29. Geller RL, Loudovaris T, Neuenfeldt S, Johnson RC, Brauker JH. Use of an immunoisolation device for cell transplantation and tumor immunotherapy. Ann N Y Acad Sci 1997. 831(31):438-451.
30. Brauker JH, Carr-Brendel VE, Martinson LA, Crudele J, Johnston WD, Johnson RC. Neovascularization of synthetic membrane directed by membrane microarchitecture. J Biomed Mater Res 1995. 29(12):1517-1524.
31. Elliott RB, Escobar L, Tan PL, Garkavenko O, Calafiore R, Basta P, Vasconcellos AV, Emerich DF, Thanos C, Bambra C. Intraperitoneal alginateencapsulated neonatal porcine islets in a placebo-controlled study with 16 diabetic cynomolgus primates. Transplant Proc 2005. 37(8):3505-3508.
32. Sörenby AK, Kumagai-Braesch M, Sharma A, Hultenby KR, Wernerson AM, Tibell AB. Preimplantation of an immunoprotective device can lower the curative dose of islets to that of free islet transplantation: studies in a rodent model. Transplantation 2008. 86(2):364-366.
33. Lee SH, Hao E, Savinov AY, Geron I, Strongin AY, Itkin-Ansari P. Human beta-cell precursors mature into functional insulin-producing cells in an immunoisolation device: implications for diabetes cell therapies. Transplantation 2009. 87(7):983-991.
34. Menard M, Dusseault J, Langlois G, Baille WE, Tam SK, Yahia L, Zhu XX, Halle JP. Role of protein contaminants in the immunogenicity of alginates. J Biomed Mater Res B Appl Biomater 2010. 93(2):333-340.
35. de Vos P, Bucko M, Gemeiner P, Navratil M, Svitel J, Faas M, Strand BL, Skjak-Braek G, Morch YA, Vikartovska A, et al. Multiscale requirements for bioencapsulation in medicine and biotechnology. Biomaterials 2009. 30(13):2559-2570.
36. Poncelet, D. Science and application of skin delivery systems. J.W. Wiechers (ed.), Allured Publishing Corporation, 2008, p. 251.
37. Narang AS, Mahato RI. Biological and biomaterial approaches for improved islet transplantation. Pharmacol Rev 2006. 58(2):194-243.
38. Mazzitelli S, Tosi A, Balestra C, Nastruzzi C, Luca G, Mancuso F, Calafiore R, Calvitti M. Production and characterization of alginate microcapsules produced by a vibrational encapsulation device. J Biomater Appl 2008. 23(2):123-145.
39. Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science 1980. 210(4472):908-910.
40. de Vos P, De Haan B, Wolters GH, van Schilfgaarde R. Factors influencing the adequacy of microencapsulation of rat pancreatic islets. Transplantation 1996. 62(7):888-893.
41. Otterlei M, Ostgaard K, Skjak-Braek G, Smidsrod O, Soon-Shiong P, Espevik T. Induction of cytokine production from human monocytes stimulated with alginate. J Immunother 1991. 10(4):286-291.
42. Robitaille R, Dusseault J, Henley N, Desbiens K, Labrecque N, Halle JP. Inflammatory response to peritoneal implantation of alginate-poly-L-lysine microcapsules. Biomaterials 2005. 26(19):4119-4127.
43. de Vos P, De Haan B, Van Schilfgaarde R. Effect of the alginate composition on the biocompatibility of alginatepolylysine microcapsules. Biomaterials 1997. 18(3):273-278.
44. King A, Sandler S, Andersson A. The effect of host factors and capsule composition on the cellular overgrowth on implanted alginate capsules. J Biomed Mater Res 2001. 57(3):374-383.
45. de Groot M, Schuurs TA, van Schilfgaarde R. Causes of limited survival of microencapsulated pancreatic islet grafts. J Surg Res 2004.121(1):141-150.
46. Kulseng B, Skjak-Braek G, Ryan L, Andersson A, King A, Faxvaag A, Espevik T. Transplantation of alginate microcapsules: generation of antibodies against alginates and encapsulated porcine islet-like cell clusters. Transplantation 1999. 67(7):978-984.
47. Silva AI, de Matos AN, Brons IG, Mateus M. An overview on the development of a bio-artificial pancreas as a treatment of insulin-dependent diabetes mellitus. Med Res Rev 2006. 26(2):181-222.
48. Soon-Shiong P, Heintz RE, Merideth N, Yao QX, Yao Z, Zheng T, Murphy M, Moloney MK, Schmehl M, Harris M, et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet 1994. 343(8903):950-951.
49. Calafiore R, Basta G, Luca G, Lemmi A, Montanucci MP, Calabrese G, Racanicchi L, Mancuso F, Brunetti P. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care 2006. 29(1):137-138.
50. Duvivier-Kali VF, Omer A, Parent RJ, O'Neil JJ, Weir GC. Complete protection of islets against allorejection and autoimmunity by a simple barium-alginate membrane. Diabetes 2001. 50(8):1698-1705.
51. van Raamsdonk JM, Cornelius RM, Brash JL, Chang PL. Deterioration of polyamino acid-coated alginate microcapsules in vivo. J Biomater Sci Polym Ed 2002. 13(8):863-884.
52. Morch YA, Donati I, Strand BL, Skjak-Braek G. Effect of Ca2+, Ba2+, and Sr2+ on alginate microbeads. Biomacromolecules 2006. 7(5):1471-1480.
53. Omer A, Duvivier-Kali VF, Trivedi N, Wilmot K, Bonner-Weir S, Weir GC. Survival and maturation of microencapsulated porcine neonatal pancreatic cell clusters transplanted into immunocompetent diabetic mice. Diabetes 2003. 52(1):69-75.
54. Siebers U, Zekorn T, Horcher A, Hering B, Bretzel RG, Zimmermann U, Federlin K. In vitro testing of rat and porcine islets microencapsulated in barium alginate beads. Transplant Proc 1992. 24(3):950-951.
55. Moskalenko V, Ulrichs K, Kerscher A, Blind E, Otto C, Hamelmann W, Demidchik Y, Timm S. Preoperative evaluation of microencapsulated human parathyroid tissue aids selection of the optimal bioartificial graft for human parathyroid allotransplantation. Transpl Int 2007. 20(8):688-696.
56. Omer A, Keegan M, Czismadia E, de Vos P, van Rooijen N, Bonner-Weir S, Weir GC. Macrophage depletion improves survival of porcine neonatal pancreatic cell clusters contained in alginate macrocapsules transplanted into rats. Xenotransplantation 2003. 10(3):240-251.
57. Tuch BE, Keogh GW, Williams LJ, Wu W, Foster JL, Vaithilingam V, Philips R. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care 2009. 32(10):1887-1889.
58. Safley SA, Cui H, Cauffiel S, Tucker-Burden C, Weber CJ. Biocompatibility and immune acceptance of adult porcine islets transplanted intraperitoneally in diabetic NOD mice in calcium alginate poly-L-lysine microcapsules versus barium alginate microcapsules without poly-L-lysine. J Diabetes Sci Technol 2008. 2(5):760-767.
59. Trivedi N, Keegan M, Steil GM, Hollister-Lock J, Hasenkamp WM, Colton CK, Bonner-Weir S, Weir GC. Islets in alginate macrobeads reverse diabetes despite minimal acute insulin secretory responses. Transplantation 2001. 71(2):203-211.
60. de Vos P, Straaten JF, Nieuwenhuizenn AG, de Groot M, Ploeg RJ, De Haan BJ, van Schilfgaarde R. Why do microencapsulated islet grafts fail in the absence of fibrotic overgrowth? Diabetes 1999. 48(7):1381-1388.
61. Tam SK, Dusseault J, Polizu S, Menard M, Halle JP, Yahia L. Impact of residual contamination on the biofunctional properties of purified alginates used for cell encapsulation. Biomaterials 2006. 27(8):1296-1305.
62. Langlois G, Dusseault J, Bilodeau S, Tam SK, Magassouba D, Halle JP. Direct effect of alginate purification on the survival of islets immobilized in alginate-based microcapsules. Acta Biomater 2009. 5(9):3433-3440.
63. Menard M, Dusseault J, Langlois G, Baille WE, Tam SK, Yahia L, Zhu XX, Halle JP. Role of protein contaminants in the immunogenicity of alginates. J Biomed Mater Res B Appl Biomater 2010. 93(2):333-340.
64. Hobbs HA, Kendall WF, Darrabie M, Opara EC. Prevention of morphological changes in alginate microcapsules for islet xenotransplantation. J Investig Med 2001. 49(6):572-575.
65. Zimmermann U, Mimietz S, Zimmermann H, Hillgartner M, Schneider H, Ludwig J, Hasse C, Haase A, Rothmund M, Fuhr G. Hydrogelbased nonautologous cell and tissue therapy. Biotechniques 2000. 29(3):564-572.
66. Lee DY, Nam JH, Byun Y. Effect of polyethylene glycol grafted onto islet capsules on prevention of splenocyte and cytokine attacks. J Biomater Sci Polym Ed 2004.15(6):753-766.
67. Siebers U, Horcher A, Brandhorst H, Brandhorst D, Hering B, Federlin K, Bretzel RG, Zekorn T. Analysis of the cellular reaction towards microencapsulated xenogeneic islets after intraperitoneal transplantation. J Mol Med 1999. 77(1):215-218.
68. Piemonti L, Leone BE, Nano R, Saccani A, Monti P, Maffi P, Bianchi G, Sica A, Peri G, Melzi R, et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 2002. 51(1):55-65.
69. Martinson L, Pauley R, Brauker J. Protection of xenografts with immunoisolation membranes. Cell Transplant 1995. 3(1):249-256.
70. Wiegand F, Kroncke KD, Kolb-Bachofen V. Macrophage-generated nitric oxide as cytotoxic factor in destruction of alginate-encapsulated islets. Protection by arginine analogs and/or coencapsulated erythrocytes. Transplantation 1993. 56(5):1206-1212.
71. Yang H, Wright JR. Co-encapsulation of Sertoli enriched testicular cell fractions further prolongs fish-to-mouse islet xenograft survival. Transplantation 1999. 67(6):815-820.
72. Chae SY, Lee M, Kim SW, Bae YH. Protection of insulin secreting cells from nitric oxide induced cellular damage by crosslinked hemoglobin. Biomaterials 2004. 25(5):843-850.
73. Dobson T, Fraga D, Saba C, Bryer-Ash M, Gaber AO, Gerling IC. Human pancreatic islets transfected to produce an inhibitor of TNF are protected against destruction by human leukocytes. Cell Transplant 2000. 9(6):857-865.
74. Giannoukakis N, Rudert WA, Ghivizzani SC, Gambotto A, Ricordi C, Trucco M, Robbins PD. Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro. Diabetes 1999. 48(9):1730-1736.
75. Cui W, Wilson JT, Wen J, Angsana J, Qu Z, Haller CA, Chaikof EL. Thrombomodulin Improves Early Outcomes after Intraportal Islet Transplantation. Am J Transplant 2009. 9(6):1308-1316.
76. Chen X, Shao W, Chen JB, Zhang L, Matthias C, Shan SG, Qi ZQ. Allotransplantation of sulphate glucomannan-alginate barium (SGA) microencapsulated rat islets for the treatment of diabetes mellitus. Immunol Invest 2009. 38(7):561-571.
77. Carlsson PO, Palm F, Andersson A, Liss P. Markedly decreased oxygen tension in transplanted rat pancreatic islets irrespective of the implantation site. Diabetes 2001. 50(3):489-495.
78. Siebers U, Horcher A, Bretzel RG, Klock G, Zimmermann U, Federlin K, Zekorn T. Transplantation of free and microencapsulated islets in rats: evidence for the requirement of an increased islet mass for transplantation into the peritoneal site. Int J Artif Organs 1993. 16(2):96-99.
79. Wang W, Gu Y, Tabata Y, Miyamoto M, Hori H, Nagata N, Touma M, Balamurugan AN, Kawakami Y, Nozawa M, Inoue K. Reversal of diabetes in mice by xenotransplantation of a bioartificial pancreas in a prevascularized subcutaneous site. Transplantation 2002. 73(1):122-129.
80. Sörenby AK, Kumagai-Braesch M, Sharma A, Hultenby KR, Wernerson AM, Tibell AB. Preimplantation of an immunoprotective device can lower the curative dose of islets to that of free islet transplantation: studies in a rodent model. Transplantation 2008. 86(2):364-366.
81. Bellmann K, Wenz A, Radons J, Burkart V, Kleemann R, Kolb H. Heat shock induces resistance in rat pancreatic islet cells against nitric oxide, oxygen radicals and streptozotocin toxicity in vitro. J Clin Invest 1995. 95(6):2840-2845.
82. Hagerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB 2007. 21(2):618-628.
83. Klein D, Ribeiro MM, Mendoza V, Jayaraman S, Kenyon NS, Pileggi A, Molano RD, Inverardi L, Ricordi C, Pastori RL. Delivery of Bcl-XL or its BH4 domain by protein transduction inhibits apoptosis in human islets. Biochem Biophys Res Commun 2004. 323(2):473-478.
84. Sigrist S, Mechine-Neuville A, Mandes K, Calenda V, Braun S, Legeay G, Bellocq JP, Pinget M, Kessler L. Influence of VEGF on the viability of encapsulated pancreatic rat islets after transplantation in diabetic mice. Cell Transplant 2003. 12(6):627-635.
85. Lembert N, Wesche J, Petersen P, Doser M, Zschocke P, Becker HD, Ammon HP. Encapsulation of islets in rough surface, hydroxymethylated polysulfone capillaries stimulates VEGF release and promotes vascularization after transplantation. Cell Transplant 2005. 14(2-3):97-108.
86. Bloch K, Papismedov E, Yavriyants K, Vorobeychik M, Beer S, Vardi P. Immobilized microalgal cells as an oxygen supply system for encapsulated pancreatic islets: a feasibility study. Artif Organs 2006. 30(9):715-718.
87. Moya ML, Garfinkel MR, Liu X, Lucas S, Opara EC, Greisler HP, Brey EM. Fibroblast growth factor-1 (FGF1) loaded microbeads enhance local capillary neovascularization. J Surg Res 2010. 160(2):208-212.
88. Smidsrød O, Skjak-Braek G. Alginate as immobilization matrix for cells. Trends Biotechnol 1990. 8(3):71-78.
89. Stabler CL, Sambanis A, Constantinidis I. Effects of alginate composition on the growth and overall metabolic activity of betaTC3 cells. Ann N Y Acad Sci 2002. 961:130-133.
90. Simpson NE, Grant SC, Gustavsson L, Peltonen VM, Blackband SJ, Constantinidis I. Biochemical consequences of alginate encapsulation: a NMR study of insulinsecreting cells. Biomaterials 2006. 27(12):2577-2586.
91. Tiedge M, Lortz S, Munday R, Lenzen S. Protection against the co-operative toxicity of nitric oxide and oxygen free radicals by overexpression of antioxidant enzymes in bioengineered insulin-producing RINm5F cells. Diabetologia 1999. 42(7):849-855.
92. Giovagnoli S, Luca G, Casaburi I, Blasi P, Macchiarulo G, Ricci M, Calvitti M, Basta G, Calafiore R, Rossi C. Long-term delivery of superoxide dismutase and catalase entrapped in poly(lactide-co-glycolide) microspheres: In vitro effects on isolated neonatal porcine pancreatic cell clusters. J Control Release 2005. 107(1):65-77.
93. Melo SS, Arantes MR, Meirelles MS, Jordao AA Jr, Vannucchi H. Lipid peroxidation in nicotinamidedeficient and nicotinamide-supplemented rats with streptozotocininduced diabetes. Acta Diabetol 2000. 37(1):33-39.
94. Kenmochi T, Miyamoto M, Mullen Y. Protection of mouse islet isografts from nonspecific inflammatory damage by recipient treatment with nicotinamide and 15deoxyspergualin. Cell Transplant 1996. 5(1):41-47.
95. Su J, Hu BH, Lowe WL Jr, Kaufman DB, Messersmith PB. Anti-inflammatory peptide-functionalized hydrogels for insulin-secreting cell encapsulation. Biomaterials 2010. 31(2):308-314.
96. Yoshioka Y, Suzuki R, Oka H, Okada N, Okamoto T, Yoshioka T, Yohei M, Hiroko S, Yasuo T, Shinsaku N, Jun-ichi M, Tadanori M. A novel cytomedical vehicle capable of protecting cells against complement. Biochem Biophys Res Commun 2003. 305(2):353-358.
97. Hwang JS, Chae SY, Lee MK, Bae YH. Synthesis of sulfonylurea conjugated copolymer via PEO spacer and its in vitro short-term bioactivity in insulin secretion from islets of Langerhans. Biomaterials 1998. 19(13):1189-1195.
98. Park KH, Kim SW, Bae YH. Interaction of sulfonylurea conjugated polymer with insulinoma cell line of MIN6 and its effect on insulin secretion. J Biomed Mater Res 2001. 55(1):72-78.
99. Kim S, Wan Kim S, Bae YH. Synthesis, bioactivity and specificity of glucagon-like peptide-1 (7-37)/polymer conjugate to isolated rat islets. Biomaterials 2005. 26(17):3597-3606.
100. Groth CG, Korsgren O, Tibell A, Tollemar J, Möller E, Bolinder J, Ostman J, Reinholt FP, Hellerström C, Andersson A. Transplantation of porcine fetal pancreas to diabetic patients. Lancet 1994. 344(8934):1402-1404.
101. Valdes-Gonzalez RA, Dorantes LM, Garibay GN, Bracho-Blanchet E, Mendez AJ, Davila-Perez R, Elliott RB, Teran L, White DJ. Xenotransplantation of porcine neonatal islets of Langerhans and Sertoli cells: a 4-year study. Eur J Endocrinol 2005. 153(3):419-427.
102. Heneine W, Tibell A, Switzer WM, Sandstrom P, Rosales GV, Mathews A, Korsgren O, Chapman LE, Folks TM, Groth CG. No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts. Lancet 1998. 352(9129):695-699.
103. Valdes-Gonzalez R, Dorantes LM, Bracho-Blanchet E, Rodriguez-Ventura A, White DJ. No evidence of porcine endogenous retrovirus in patients with type 1 diabetes after long-term porcine islet xenotransplantation. J Med Virol 2010. 82(2): 331-334.
104. Omer A, Duvivier-Kali VF, Trivedi N, Wilmot K, Bonner-Weir S, Weir GC. Survival and maturation of microencapsulated porcine neonatal pancreatic cell clusters transplanted into immunocompetent diabetic mice. Diabetes 2003. 52(1):69-75.
105. Foster JL, Williams G, Williams LJ, Tuch BE. Differentiation of transplanted microencapsulated fetal pancreatic cells. Transplantation 2007. 83(11):1440-1448.
106. Elliott RB, Escobar L, Tan PL, Muzina M, Zwain S, Buchanan C. Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation 2007. 14(2):157-161.
107. Cheung AT, Dayanandan B, Lewis JT, Korbutt GS, Rajotte RV, Bryer-Ash M, Boylan MO, Wolfe MM, Kieffer TJ. Glucose-dependent insulin release from genetically engineered K cells. Science 2000. 290(5498):1959-1962.
108. Dor Y, Brown J, Martinez OI, Melton DA. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 2004. 429(6987):41-46.
109. Georgia S, Bhushan A. Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. J Clin Invest 2004. 114(7):963-968.
110. Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, McKay R. Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets. Science 2001. 292(5520):1389-1394.
111. D'Amour KA, Bang AG, Eliazer S, Kelly OG, Agulnick AD, Smart NG, Moorman MA, Kroon E, Carpenter MK, Baetge EE. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol 2006. 24(11):1392-1401.
112. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, Eliazer S, Young H, Richardson M, Smart NG, Cunningham J, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008. 26(4):443-452.
113. Chayosumrit M, Tuch B, Sidhu K. Alginate microcapsule for propagation and directed differentiation of hESCs to definitive endoderm. Biomaterials 2010. 31(3):505-514.
114. Dean SK, Yulyana Y, Williams G, Sidhu KS, Tuch BE. Differentiation of encapsulated embryonic stem cells after transplantation. Transplantation 2006. 82(9):1175-1184.
115. Wang X, Wang W, Ma J, Guo X, Yu X, Ma X. Proliferation and differentiation of mouse embryonic stem cells in APA microcapsule: a model for studying the interaction between stem cells and their niche. Biotechnol Prog 2006. 22(3):791-800.
116. Maguire T, Novik E, Schloss R, Yarmush M. Alginate-PLL microencapsulation: effect on the differentiation of embryonic stem cells into hepatocytes. Biotechnol Bioeng 2006. 93(3):581-591.
117. Dang SM, Gerecht-Nir S, Chen J, Itskovitz-Eldor J, Zandstra PW. Controlled, scalable embryonic stem cell differentiation culture. Stem Cells 2004. 22(3):275-282.
118. Selden C, Khalil M, Hodgson H. Three dimensional culture upregulates extracellular matrix protein expression in human liver cell lines a step towards mimicking the liver in vivo? Int J Artif Organs 2000. 23(11):774-781.
119. Glicklis R, Shapiro L, Agbaria R, Merchuk JC, Cohen S. Hepatocyte behavior within three-dimensional porous alginate scaffolds. Biotechnol Bioeng 2000. 67(3):344-353.
120. Batorsky A, Liao J, Lund AW, Plopper GE, Stegemann JP. Encapsulation of adult human mesenchymal stem cells within collagen-agarose microenvironments. Biotechnol Bioeng 2005. 92(4):492-500.
121. Vaithilingam V, Oberholzer J, Guillemin GJ, Tuch BE. Beneficial effects of desferrioxamine on encapsulated human islets in vitro and in vivo study. Am J Transplant 2010. 10(9):1961-1969.
122. Vaithilingam V, Kollarikova G, Qi M, Lacik I, Oberholzer J, Guillemin GJ, Tuch BE. Effect of prolonged gelling time on the intrinsic properties of barium alginate microcapsules and its biocompatibility. J Microencapsul 2011. In press).
123. Vaithilingam V, Oberholzer J, Guillemin GJ, Tuch BE. The humanized NOD/SCID mouse as a preclinical model to study the fate of encapsulated human islets. Rev Diabet Stud 2010. 7(1):62-73.